TY - JOUR
T1 - 2-year outcomes of MitraClip as a bridge to heart transplantation
T2 - The international MitraBridge registry
AU - Munafò, Andrea Raffaele
AU - Scotti, Andrea
AU - Estévez-Loureiro, Rodrigo
AU - Adamo, Marianna
AU - Hernàndez, Antonio Portolés
AU - Peregrina, Estefanìa Fernàndez
AU - Gutierrez, Lola
AU - Taramasso, Maurizio
AU - Fam, Neil P.
AU - Ho, Edwin C.
AU - Asgar, Anita
AU - Vitrella, Giancarlo
AU - Raineri, Claudia
AU - Chizzola, Giuliano
AU - Pezzola, Elisa
AU - Le Ruz, Robin
AU - Montalto, Claudio
AU - Oreglia, Jacopo A.
AU - Fraccaro, Chiara
AU - Giannini, Cristina
AU - Fiorelli, Francesca
AU - Rubbio, Antonio Popolo
AU - Ooms, J. F.
AU - Compagnone, Miriam
AU - Marcelli, Chiara
AU - Maffeo, Diego
AU - Bettari, Luca
AU - Fürholz, Monika
AU - Arzamendi, Dabit
AU - Guerin, Patrice
AU - Tamburino, Corrado
AU - Petronio, A. Sonia
AU - Grasso, Carmelo
AU - Agricola, Eustachio
AU - Van Mieghem, Nicolas M.
AU - Tarantini, Giuseppe
AU - Praz, Fabien
AU - Pascual, Isaac
AU - Potena, Luciano
AU - Colombo, Antonio
AU - Maisano, Francesco
AU - Metra, Marco
AU - Margonato, Alberto
AU - Crimi, Gabriele
AU - Saia, Francesco
AU - Godino, Cosmo
N1 - Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background: In the first report from the MitraBridge registry, MitraClip as a bridge to heart transplantation (HTx) proved to be at 1-year an effective treatment strategy for 119 patients with advanced heart failure (HF) who were potential candidates for HTx. We aimed to determine if benefits of MitraClip procedure as a bridge-to-transplant persist up to 2-years. Methods: By the end of the enrollment period, a total of 153 advanced HF patients (median age 59 years, left ventricular ejection fraction 26.9 ± 7.7%) with significant secondary mitral regurgitation, who were potential candidates for HTx and were treated with MitraClip as a bridge-to-transplant strategy, were included in the MitraBridge registry. The primary endpoint was the 2-year composite adverse events rate of all-cause death, first hospitalization for HF, urgent HTx or LVAD implantation. Results: Procedural success was achieved in 89.5% of cases. Thirty-day mortality was 0%. At 2-year, Kaplan-Meier estimates of freedom from primary endpoint was 47%. Through 24 months, the annualized rate of HF rehospitalization per patient-year was 44%. After an overall median follow-up time of 26 (9–52) months, elective HTx was successfully performed in 30 cases (21%), 19 patients (13.5%) maintained or obtained the eligibility for transplant, and 32 patients (22.5%) no longer had an indication for HTx because of significant clinical improvement. Conclusions: After 2-years of follow-up, the use of MitraClip as a bridge-to-transplant was confirmed as an effective strategy, allowing elective HTx or eligibility for transplant in one third of patients, and no more need for transplantation in 22.5% of cases.
AB - Background: In the first report from the MitraBridge registry, MitraClip as a bridge to heart transplantation (HTx) proved to be at 1-year an effective treatment strategy for 119 patients with advanced heart failure (HF) who were potential candidates for HTx. We aimed to determine if benefits of MitraClip procedure as a bridge-to-transplant persist up to 2-years. Methods: By the end of the enrollment period, a total of 153 advanced HF patients (median age 59 years, left ventricular ejection fraction 26.9 ± 7.7%) with significant secondary mitral regurgitation, who were potential candidates for HTx and were treated with MitraClip as a bridge-to-transplant strategy, were included in the MitraBridge registry. The primary endpoint was the 2-year composite adverse events rate of all-cause death, first hospitalization for HF, urgent HTx or LVAD implantation. Results: Procedural success was achieved in 89.5% of cases. Thirty-day mortality was 0%. At 2-year, Kaplan-Meier estimates of freedom from primary endpoint was 47%. Through 24 months, the annualized rate of HF rehospitalization per patient-year was 44%. After an overall median follow-up time of 26 (9–52) months, elective HTx was successfully performed in 30 cases (21%), 19 patients (13.5%) maintained or obtained the eligibility for transplant, and 32 patients (22.5%) no longer had an indication for HTx because of significant clinical improvement. Conclusions: After 2-years of follow-up, the use of MitraClip as a bridge-to-transplant was confirmed as an effective strategy, allowing elective HTx or eligibility for transplant in one third of patients, and no more need for transplantation in 22.5% of cases.
KW - Advanced heart failure
KW - Heart transplantation
KW - MitraClip
KW - Secondary mitral regurgitation
KW - Transcatheter mitral valve intervention
UR - http://www.scopus.com/inward/record.url?scp=85165005877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165005877&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2023.131139
DO - 10.1016/j.ijcard.2023.131139
M3 - Article
C2 - 37355239
AN - SCOPUS:85165005877
SN - 0167-5273
VL - 390
JO - International Journal of Cardiology
JF - International Journal of Cardiology
M1 - 131139
ER -